You position:
Home
/
/
Medlab Asia & Asia Health: Pluslife Strengthening STIs Control in ASEAN Countries

Medlab Asia & Asia Health: Pluslife Strengthening STIs Control in ASEAN Countries

  • Categories:News & Events
  • Author:
  • Origin:
  • Time of issue:2023-08-18 09:19
  • Views:

(Summary description)

Medlab Asia & Asia Health: Pluslife Strengthening STIs Control in ASEAN Countries

(Summary description)

  • Categories:News & Events
  • Author:
  • Origin:
  • Time of issue:2023-08-18 09:19
  • Views:
Information

At this year’s Medlab Asia & Asia Health from August 16 to 18 in Bangkok, Pluslife is showcasing its latest molecular Point-of-Care (POC) solution to visitors at Hall 7. Visitors can discover the unique features of Pluslife’s Mini Dock, Dock Pro 8, and STI test cards in different application scenarios. 

 

 

Medlab Asia & Asia Health serves as the largest platform for the healthcare and laboratory industry in the ASEAN (Association of Southeast Asian Nations) region, bringing together worldwide industry experts and medical professionals to exchange insights on the latest advances in developing infection-free medical devices and further explore collaboration options. This year’s in-person edition attracts over 7500+ attendees and 300+ exhibiting companies from 50+ countries, providing opportunities for accessing a wide range of cutting-edge medical products and services.

 

 

Similar to other ASEAN countries, STIs continue to be a severe public health problem in Thailand. In recent years, the use of innovative tools and techniques including rapid molecular POCT testing plays an essential role in strengthening the first line of defense. Pluslife Molecular POCT Solution delivers qPCR-level test results in 7-35 minutes, which enables patients to receive same-day diagnosis and treatment in as short as 1 hour, and encourages the sexually active individuals to remain adherent to regular testing for STIs. With the capacity of early detection for various presumptive STIs cases, including CT/NG/UU, HPV16/18/45, and GBS, Pluslife helps to increase the coverage of STIs control in local communities.

 

 

At yesterday’s exhibition, Pluslife was delighted to receive impressive recognition for its comprehensive test menu. Based on the self-developed, patented RHAM technology, Pluslife has developed a series of combo nucleic acid test cards, including SARS-CoV-2/Flu A/Flu B, RSV/Flu A/Flu B, etc., which support simultaneous detection of two or more pathogens. With Pluslife’s combo nucleic acid test cards, physicians can make early evidence-based diagnoses for various infectious diseases and provide pathogen-specific treatment that improves medical prognosis.

 

Driven by the passion for staying ahead of molecular diagnostics, Pluslife is committed to constantly developing molecular POCT solutions for complex challenges in STIs. Our next upcoming exhibition will be the Medical Philippines Expo 2023 from Aug 23 to 35 in Manila, Philippines.

Tel: +86-20-31703986
E-mail:

market@pluslife.com

  (Business Enquiry)

service@pluslife.com

  (After-Sales&Technical Support)

Add: 3F-Block E, Runhui Science & Technology Park, No. 18 Shenzhou RD, Huangpu District, Guangzhou, Guangdong, China

PLUSLIFE

Monday - Friday, 08:00 -20:00

Copyright © 2021 Guangzhou Pluslife Technology  Co., Ltd.  粤ICP备19038432号